Paris
France
24
2025-05-01
The entities that hold a legal rights for patent applications filed by inventor MIOSSEC Patrick:
Patrick MIOSSEC from Paris, FR has applied for patents for these inventions. The list has both pending applications and granted patents:
METHOD FOR INDUCING WEIGHT LOSS IN A TYPE 2 DIABETES MELLITUS PATIENT
#2 | 2023-01-26PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTS
#3 | 2022-11-03PHARMACEUTICAL COMBINATION FOR IMPROVING GLYCEMIC CONTROL AS ADD-ON THERAPY TO BASAL INSULIN
#4 | 2022-02-24USE OF AVE0010 FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2
#5 | 2020-11-12USE OF AVE0010 FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2
#6 | 2020-10-29PHARMACEUTICAL COMBINATION FOR IMPROVING GLYCEMIC CONTROL AS ADD-ON THERAPY TO BASAL INSULIN
#7 | 2020-10-22PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTS
#8 | 2019-05-09Pharmaceutical Combination for Use in Glycemic Control in Diabetes Type 2 Patients
#9 | 2019-02-21PREVENTION OF HYPOGLYCEMIA IN DIABETES MELLITUS TYPE 2 PATIENTS
#10 | 2019-01-31Use of AVE0010 for the Treatment of Diabetes Mellitus Type 2
#11 | 2018-11-29PHARMACEUTICAL COMBINATION FOR IMPROVING GLYCEMIC CONTROL AS ADD-ON THERAPY TO BASAL INSULIN
#12 | 2018-01-04PREVENTION OF HYPOGLYCAEMIA IN DIABETES MELLITUS TYPE 2 PATIENTS
#13 | 2017-05-25Pharmaceutical Combination for Use in Glycemic Control in Diabetes Type 2 Patients
#14 | 2017-05-04Use of AVE0010 for the treatment of diabetes mellitus type 2
#15 | 2017-03-23PREVENTION OF HYPOGLYCEMIA IN DIABETES MELLITUS TYPE 2 PATIENTS
#16 | 2014-05-29USE OF AVE0010 FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2
#17 | 2013-08-08Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
#18 | 2013-04-04PREVENTION OF HYPOGLYCEMIA IN DIABETES MELLITUS TYPE 2 PATIENTS
#19 | 2013-03-14PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTS
#20 | 2013-02-14PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT OF DIABETES TYPE 2 PATIENTS
#21 | 2013-01-24Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
#22 | 2013-01-03Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
#23 | 2012-11-01PREVENTION OF HYPOGLYCAEMIA IN DIABETES MELLITUS TYPE 2 PATIENTS
#24 | 2010-10-28USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH IMMUNOLOGICAL DISORDERS
13601 ⎘